These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32484056)

  • 1.
    Barbirou M; Sghaier I; Bedoui S; Ben Abderrazek R; Kraiem H; Farah A; Hassiki R; Mokrani A; Mezlini A; Almawi WY; Loueslati-Yacoubi B; Bouhaouala-Zahar B
    Tumour Biol; 2020 Jun; 42(6):1010428320925237. PubMed ID: 32484056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Western influenced lifestyle and Kv2.1 association as predicted biomarkers for Tunisian colorectal cancer.
    Barbirou M; Woldu HG; Sghaier I; Bedoui SA; Mokrani A; Aami R; Mezlini A; Yacoubi-Loueslati B; Tonellato PJ; Bouhaouala-Zahar B
    BMC Cancer; 2020 Nov; 20(1):1086. PubMed ID: 33172410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin: a welcome addition to our therapeutic armamentarium.
    Chu E
    Clin Colorectal Cancer; 2002 Aug; 2(2):72. PubMed ID: 12453318
    [No Abstract]   [Full Text] [Related]  

  • 4. A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels.
    Ng SL; Burns WI; Snyder RD; Newnham GM; McLachlan SA; Liew D; Dowling AJ
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):172-9. PubMed ID: 22524576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma.
    Kouri M; Pyrhönen S; Kuusela P
    J Surg Oncol; 1992 Feb; 49(2):78-85. PubMed ID: 1738240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short article: Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy.
    Catalano C; da Silva Filho MI; Jiraskova K; Vymetalkova V; Levy M; Liska V; Vycital O; Naccarati A; Vodickova L; Hemminki K; Vodicka P; Weber ANR; Försti A
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):838-842. PubMed ID: 29762254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer.
    Suenaga M; Cao S; Zhang W; Matsusaka S; Okazaki S; Berger MD; Miyamoto Y; Schirripa M; Barzi A; Yamamoto N; Yamaguchi T; Lenz HJ
    Pharmacogenet Genomics; 2021 Jan; 31(1):10-16. PubMed ID: 32732498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
    Falvella FS; Cheli S; Martinetti A; Mazzali C; Iacovelli R; Maggi C; Gariboldi M; Pierotti MA; Di Bartolomeo M; Sottotetti E; Mennitto R; Bossi I; de Braud F; Clementi E; Pietrantonio F
    Br J Clin Pharmacol; 2015 Sep; 80(3):581-8. PubMed ID: 25782327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
    Sun Z; Zhang N
    World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An exploratory study of the association between KCNB1 rs1051295 and type 2 diabetes and its related traits in Chinese Han population.
    Zhang YX; Liu Y; Dong J; Wang YX; Wang J; Zhuang GQ; Han SJ; Guo QQ; Luo YX; Zhang J; Peng XX; Zhang L; Yan YX; Yang XH; Wang H; Han X; Liu GX; Kang YH; Liu YQ; Weng SF; Zhang H; Zhang XQ; Jia KB; Wang L; Zhao L; Xiao ZX; Zhang SH; Wu HH; Lai QX; Qi N; Wang W; Gaisano H; Liu F; He Y
    PLoS One; 2013; 8(2):e56365. PubMed ID: 23431371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: a preliminary report.
    Cai X; Fang JM; Xue P; Song WF; Hu J; Gu HL; Yang HY; Wang LW
    Eur Rev Med Pharmacol Sci; 2014; 18(8):1247-58. PubMed ID: 24817302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX.
    Onesti CE; Botticelli A; La Torre M; Borro M; Gentile G; Romiti A; Lionetto L; Petremolo A; Occhipinti M; Roberto M; Falcone R; Simmaco M; Marchetti P; Mazzuca F
    Anticancer Drugs; 2017 Mar; 28(3):322-326. PubMed ID: 27845948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer.
    Garziera M; Virdone S; De Mattia E; Scarabel L; Cecchin E; Polesel J; D'Andrea M; Pella N; Buonadonna A; Favaretto A; Toffoli G
    Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28653974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic arterial infusion with oxaliplatin, folinic acid, and 5-fluorouracil in patients with hepatic metastases from colorectal cancer: role of carcino-embryonic antigen in assessment of response.
    Kern W; Beckert B; Lang N; Waggershauser T; Braess J; Schalhorn A; Hiddemann W
    Anticancer Res; 2000; 20(6D):4973-5. PubMed ID: 11326650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.
    Boige V; Mendiboure J; Pignon JP; Loriot MA; Castaing M; Barrois M; Malka D; Trégouët DA; Bouché O; Le Corre D; Miran I; Mulot C; Ducreux M; Beaune P; Laurent-Puig P
    J Clin Oncol; 2010 May; 28(15):2556-64. PubMed ID: 20385995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folfox4 regimen administered through combined hepatic arterial and systemic infusion for treatment of colorectal cancer with unresectable liver metastases.
    Guan M; Chen SC; Ying HY; Zhao L; Li XY; Zhou JF; Shao YJ; Yang XD; Lin Y; Ning XH; Bai CM
    Chin Med J (Engl); 2012 Oct; 125(20):3640-5. PubMed ID: 23075717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients.
    Zhang L; Zhao J; Yu B; Song X; Sun G; Han L; Wang L; Dong S
    Cancer Genet; 2017 Dec; 218-219():51-57. PubMed ID: 29153096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin.
    Gordon MA; Zhang W; Yang D; Iqbal S; El-Khouiery A; Nagashima F; Lurje G; Labonte M; Wilson P; Sherrod A; Ladner RD; Lenz HJ
    Pharmacogenomics; 2011 Jan; 12(1):27-39. PubMed ID: 21174620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of KCNB1 polymorphisms with lipid metabolisms and insulin resistance: a case-control design of population-based cross-sectional study in Chinese Han population.
    Yu Y; Wang J; Kang R; Dong J; Zhang Y; Liu F; Yan Y; Zhu R; Xia L; Peng X; Zhang L; He D; Gaisano HY; Chen Z; He Y
    Lipids Health Dis; 2015 Sep; 14():112. PubMed ID: 26377690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.